Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-02-22 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi and Teva Pharmaceuticals announcing new clinical trial results for their drug candidate 'duvakitug' presented at the ECCO 2025 congress. It details efficacy and safety data from a phase 2b study. As it is a corporate announcement regarding clinical trial progress and research findings, it falls under the category of general regulatory announcements/press releases, which is best classified as RNS (Regulatory Filings) in the absence of a more specific 'Clinical Trial Update' category.
2025-02-22 English
6-K
Regulatory Filings
2025-02-20 English
Communiqué de presse : Sanofi et CD&R annoncent la signature de l’accord d’achat des actions d’Opella
M&A Activity Classification · 100% confidence The document is a press release from Sanofi announcing the signing of a share purchase agreement for the sale of a 50% stake in its subsidiary, Opella, to CD&R. This is a clear announcement of a merger and acquisition (M&A) transaction. According to the provided filing definitions, documents related to merger proposals or takeover bids are classified as M&A Activity (TAR).
2025-02-19 French
Press Release: Sanofi and CD&R sign Opella share purchase agreement
M&A Activity Classification · 100% confidence The document is a press release announcing the signing of a share purchase agreement for the sale of a 50% stake in Opella by Sanofi to CD&R. This constitutes a corporate transaction involving a divestiture or merger-related activity. According to the filing definitions, announcements related to merger proposals or takeover bids (including divestitures) fall under the M&A Activity (TAR) category.
2025-02-19 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled 'Déclaration des transactions sur actions propres' (Declaration of transactions on own shares) and provides a detailed table of share repurchase transactions conducted by Sanofi. This matches the definition for 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2025-02-18 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is titled 'Disclosure of trading in own shares' and provides a detailed table of share repurchase transactions, including dates, volumes, and prices. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2025-02-18 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.